You could be eligible to participate in a psychedelic research trial. We’ve compiled a list here of all the current or planned clinical trials on MDMA, psilocybin, LSD, ibogaine, and more.
Finding the best fit therapist for you can be a daunting task, whether or not the work involves psychedelics. In this article, we share insights into finding the best therapist for you - navigating the degrees of health professionals, reflecting on your own needs, listing questions to ask when interviewing a therapist, and more.
The Food and Drug Administration (FDA) and the National Institutes of Health (NIH) communicated publicly about psychedelic drug development and current thinking around safety, therapeutic use, and research. The FDA Division of Psychiatry Products provided information in a workshop about how to design and efficiently study psychedelics for potential medical use.
Six phase 2 trials investigated MDMA-assisted psychotherapy for treatment of PTSD. Results that led to Breakthrough Therapy designation are now published.
Until recently, the only opportunity to train and work legally as a psychedelic therapist was in clinical trials. That will likely change over time as expanded access becomes the next step for current trials (evaluating MDMA and psilocybin) and if psychedelic-assisted therapies become FDA approved.
Here, take these pills. It will make you better. Likely you’ve heard these phrases before if you’re living in a medicalized society. For whatever ails you, there is a pill or an entire arsenal of medications that your doctor may prescribe. Some of these drugs are life-saving remedies with biological targets that interrupt disease progression
Patchwork Art from MAPS Therapist Training Program 2017Photo Credit: Alyssa Gursky Findings from the last study in a series of six Phase 2 trials of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder (PTSD) was published today in the Journal of Psychopharmacology . The clinical trial in Boulder, Colorado (MP-12) enrolled 28 participants suffering from
The first clinical trial in adults on the autism spectrum investigating MDMA, or any psychedelic substance for that matter, was published in Psychopharmacology this week . This groundbreaking research looked at whether MDMA combined with psychotherapy could help with the severe social anxiety that autistic adults commonly experience. The drug-therapy combo wasn’t intended to be
Originally published on Chacruna.net by Dr. Alli Feduccia Clinical trials of MDMA, psilocybin, ketamine, and ayahuasca are offering a glimpse that the future may hold psychiatric treatments far different from daily drug prescriptions currently used for anxiety and addictive disorders. Research is only beginning to unravel how these experiences in altered states of consciousness produce large shifts
A common question about the recent wave of psychedelic research is, “how do these mind-altering substances work in the brain to produce a rapid reduction of symptoms and long-lasting improvements for a variety of mental health disorders?” Beyond some scientifically well-founded hypotheses and pure speculation, we haven’t had enough experimental evidence on psychedelics to draw